why choose us

First received: December 6, 2022

Clinical Trial: A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Human Papillomavirus Infection

Study Type: Interventional


Official Title: A Multi-centre, Blinded, Randomized and Gardasil-controlled Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety Profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Huma

Brief Summary: This study is to demonstrate that the administration of the investigational vaccine can reduce the Combined Incidence of HPV types 6/11/16/18/31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3), Adenocarcinoma in Situ (AIS), Invasive Cervical Carcinoma, high-grade Vulvar Intraepithelial Neoplasia (VIN 2/3), high-grade Vaginal Intraepithelial Neoplasia (VaIN 2/3), high-grade Anal Intraepithelial Neoplasia (AIN 2/3), vulvar cancer, vaginal cancer or anal cancer.

Read more